‘We are facing the global shift of the SARS-CoV-2 variant — from D614 to G614. The G614 variant is more infectious in laboratory settings; whether it means increased viral spread in humans is unconfirmed. Current evidence says that the G614 variant is not any deadlier than D614. And so, treatment options should not be any more different. Both the D614 and G614 variants should react similarly to vaccines, studies suggest, as the mutation does not change the immunogenic part of the spike protein; that is, the receptor-binding domain (RBD).’
[This is a survey of literature by a young post-grad Malaysian. It gives a rounded picture of the D614G mutation without using too much jargon. Must counter check the accuracy of what's stated against the originals.]
Read here (Medium, July 31, 2020)
